Geographic Atrophy

You may be wondering: What is all this hype about geographic atrophy (GA)? If you are, let us look at the enigma.

Arshad M. Khanani, MD, MA, FASRS, sat down with Optometry Times to discuss the recent FDA approval of avacincaptad pegol intravitreal solution for treatment of geographic atrophy.

Paul Hahn, MD, PhD, shared insights on research comparing the relative efficacy of pegcetacoplan versus avacincaptad pegol in patients with geographic atrophy presented at the 2023 ASRS annual meeting.

According to the company, the therapeutic is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two phase 3 clinical trials.

Data from the 30 month GALE extension study indicated that continuous treatment with pegcetacoplan injection showed increasing beneficial effects over that timeframe in patients with geographic atrophy (GA).

The company has completed evaluation on candidates and selected a single drug candidate to move forward into clinical trials.

A single, consistent modality leads to better geographic atrophy tracking.

Jay M. Haynie, OD, FAAO, FORS, caught up with Peg Achenbach, OD, FAAO, while at the 2023 Victoria Conference to share highlights from his presentation on staying current with the AMD landscape.

CT1812 is an experimental, oral therapy for the treatment of geographic atrophy secondary to dry age-related macular edema.

Clinical benefit of complement inhibition has been demonstrated in clinical trials, but there are possible consequences to consider.

How to diagnose and monitor progression.

Diagnose, monitor, comanage—optometrists support patients throughout all stages of the disease.

David S. Boyer, MD, shares highlights from the symposium on advances in the geographic atrophy space, which he presented during the 17th annual Controversies in Modern Eye Care meeting.

The GA Won’t Wait campaign is designed to help older adults and their families understand and recognize the symptoms of this progressive and irreversible disease.

Catch up on what happened in optometry during the week of April 17-April 21.

One way to advance the current understanding of GA is to study how disease progression varies among related individuals.

A look back on what happened in optometry during the week of April 10-April 14.

Pegcetacoplan’s recent FDA approval creates an option for patients with dry AMD.

A look back on what happened in optometry during the week of April 3-April 7.

Euin Cheong, OD, weighs in on the Syfvore approval for geographic atrophy and how optometrists should participate in geographic atrophy care.

Imaging can elucidate visual prognosis and disease progression risk.

These disorders account for most of the vision loss in working-age and elderly Americans.

Mohammed Rafieetary, OD, shares key takeaways from his SECO 2023 presentation, "Advancing the understanding of geographic atrophy."

Following the submission of the 24-month phase 3 data in November 2022, Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD.

Look out for at-risk patients and prepare to establish treatment protocols.

The submission of 24-month efficacy data from DERBY and OAKS is classified as a Major Amendment to the New Drug Application, which delays the PDUFA target action date until February 2023.

Jessica Steen, OD, FAAO, shares highlights from her VEW 2022 presentation, "Ophthalmic therapeutics update."

Latest data from phase 3 studies finds increased effects over time with intravitreal pegcetacoplan for geographic atrophy secondary to age-related macular degeneration.

If approved, pegcetacoplan—an investigational, targeted C3 therapy—will be the first-ever treatment for GA.

Advancements enable better diagnosis, treatment of patients.